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Extracutaneous Chronic Graft-versus-Host Disease
after a 24-Week Course of Extracorporeal
Photopheresis—Results of a Crossover
Randomized Study
Hildegard T. Greinix,1 Koen van Besien,2 Ahmet H. Elmaagacli,3 Uwe Hillen,3 Andrew Grigg,4
Robert Knobler,1 Dennis Parenti,5 Vijay Reddy,6 Koen Theunissen,7 Mauricette Michallet,8
Mary E. D. Flowers,9 for the UVADEX Chronic GVHD Study GroupIn a prior multicenter randomized controlled trial, we found that a 12-week course of extracorporeal photo-
pheresis (ECP) plus standard immunosuppressive therapy resulted in several beneficial outcomes in patients
with corticosteroid-refractory/intolerant/dependent chronic graft-versus-host disease (GVHD). Here, we
report the results of an open-label crossover ECP study in 29 eligible participants randomized initially to
the standard of care non-ECP (control) arm. Eligible for the crossover ECP study were control arm patients
who either (1) had progression of cutaneous chronic GVHD (cGVHD), defined as .25% worsening from
baseline as measured by the percent change in the total skin score (TSS) at any time, or (2) had less than
15% improvement in the TSS, or had a#25% reduction in corticosteroid dose at week 12 of the initial study.
ECP was administered 3 times during week 1, then twice weekly until week 12, followed by 2 treatments
monthly until week 24. The median age of the study cohort was 43 (20-67) years and 90% had extensive
cGVHD. The median months from onset of cGVHD to start of ECP were 26 (range: 4-79). Twenty-five of
29 patients (86%) completed the 24-week course of ECP. Complete or partial skin response at week 24
was noted in 9 patients (31%). The median percent of decrease in TSS from baseline to weeks 12 and 24
was 27.9 and 225.8, respectively. In 4 (17%) and 8 (33%) patients, a $50% reduction in corticosteroid
dose at weeks 12 and 24 was observed. Extracutaneous cGVHD response was highest in oral mucosa
with 70% complete and partial resolution after week 24. In conclusion, progressive improvement in cutane-
ous and extracutaneous cGVHDwas observed after a 24-week course of ECP in patients who previously had
no clinical improvement or exhibited worsening of cGVHD while receiving standard immunosuppressive
therapy alone in a randomized study. These results confirm previous findings and support the notion that
prolonged ECP appears to be necessary for optimal therapeutic effects in corticosteroid-refractory cGVHD
patients.
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immunodeficiency. Established first-line therapy of
cGVHD consists of corticosteroids either alone or in
combination with calcineurin inhibitors [2,4,5]. The
median duration of systemic immunosuppressive
treatment is 2 to 3 years from the initial diagnosis of
cGVHD, which is a concern for its contribution to
the risk of infections and other associated treatment-
related morbidities [6]. Although first-line treatment
of cGVHD is based on controlled clinical trials, sal-
vage therapy has been nearly solely based on phase II
studies or retrospective analyses [7]. Despite reported
efficacy of many immunosuppressive and immuno-
modulatory treatments in heterogeneous and often
small cohorts of patients with cGVHD, no single agent
has consistently demonstrated a steroid-sparing effect
in patients with cGVHD [1,7].
During the past few years, a substantial number of
patients with steroid-refractory or steroid-dependent
cGVHD has reportedly been treated with extracorpo-
real photopheresis (ECP) [8-13]. The mechanisms
of action of ECP is thought to include induction of
apoptosis in all leukocyte subsets, inhibition of
proinflammatory cytokines, production of anti-
inflammatory cytokines, and induction of regulatory
T cells [14,15]. In an elegant GVHD mouse model,
Gatza and colleagues [15] showed that ECP reduced
mortality and reversed established experimental
GVHD by directly increasing donor-derived regula-
tory T cells and indirectly by reducing donor effector
lymphocytes, thus improving immune recovery.
Salvage treatment of steroid-refractory cGVHD
with ECP achieved consistently high responses in
cutaneous and extracutaneous manifestations includ-
ing sclerodermatous skin features [7-13]. In addition,
ECP has been found to be well tolerated. In a
randomized, standard therapy-controlled trial, we re-
cently reported that ECP treatment of cGVHD was
associated with improvement in the cutaneous mani-
festations, reduction in corticosteroid use, improve-
ment in quality of life, and a parallel improvement of
extracutaneous manifestations of the disease at week
12 [16]. Of note, patients who received up to 24 weeks
of ECP therapy in that study showed continuous
improvement of GVHD, suggesting that longer treat-
ment duration may be necessary for optimal response
in patients with more advanced disease. In line with
these observations, long-term administration of ECP
to patients with atopic dermatitis or scleroderma is
also reportedly associated with increased response
rates [17,18].
Here, we report the results of a prospective open-
label crossover ECP study for eligible participants who
were initially randomized to the standard of care (non-
ECP) treatment arm (corticosteroids with/without
calcineurin inhibitors and with/without mycopheno-late mofetil) of the prior ECP study [16]. Eligible pa-
tients were those who either demonstrated no clinical
improvement after at least 12 weeks in the non-ECP
study arm or experienced worsening of cutaneous
cGVHD while receiving standard-of-care treatment
alone according to prespecified study criteria of the
initial randomized ECP trial [16].PATIENTS AND METHODS
Patient Characteristics
All 29 patients had cutaneous cGVHD and had
been enrolled in the non-ECP arm of a previously re-
ported randomized clinical trial investigating ECP for
treatment of corticosteroid-refractory, dependent,
or intolerant cGVHD (referred in this report as the
‘‘initial randomized trial’’) [16]. Patients were eligible
to enroll in this subsequent crossover open-label ECP
trial if they had (1) progression of cutaneous cGVHD
defined as.25%worsening from baseline as measured
by the percent change in the total skin score (TSS),
or (2) after week 12 had an inadequate response of
cutaneous cGVHD as defined by\15% improvement
in the TSS compared with baseline, or a#25% reduc-
tion in corticosteroid dose. Additional inclusion crite-
ria included: (1) adequate renal, hepatic, pulmonary,
and cardiac function to enable the subject to tolerate
the extracorporeal volume shifts associated with ECP,
(2) white blood cell (WBC) count $1000/mm3 and
platelets $25,000/mm3, and (3) Karnofsky Perfor-
mance score $30%. Patients were excluded from the
crossover open-label ECP study if they had withdrawn
from the initial randomized trial with inadequate re-
sponse before completion of 12 weeks of treatment.
Other exclusion criteria were intolerance to methoxsa-
len, heparin, or citrate products, active gastrointestinal
bleeding, previous treatment with ECP, pregnancy, or
lactation.
Twenty-nine of the initial 47 (61%) non-ECP
study arm patients entered the study, including 6
(21%) with disease progression and 23 (79%) with in-
adequate response to non-ECP treatment in the initial
randomized trial (Figure 1). None of the patients re-
ceived additional therapy for GVHD between the ini-
tial randomized study and the start of the open-label
ECP treatment. Corticosteroid tapering during treat-
ment with ECP was guided by cGVHD manifestation
at the discretion of the treating physician. Twenty-five
of 29 (86%) patients completed 24 weeks of ECP treat-
ment. One patient each died (suicide) or withdrew
consent, whereas 2 had GVHD progression and thus
did not complete 24 weeks of ECP treatment.
Conventional antiinfective prophylaxis and sup-
portive care were governed by institutional guidelines.
Patients were not permitted to use topical
Figure 1. Disposition of patients enrolled in initial randomized and
crossover open-label ECP study.
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consent, and the protocol was approved by the institu-
tional review board of each participating institution.Study Design and Objectives
The initial randomized, multicenter study was
conducted at 23 transplant centers inNorth and South
America, Europe, andAustralia, and was sponsored by
Therakos, Inc. (Raritan, NJ). Fifteen of the 23 initial
transplant centers contributed patients to this cross-
over open-label ECP study (Appendix 1). Patients
were enrolled from September 2003 to May 2006.
The primary objective of the current salvage study
was to provide access to ECP to patients who had
previously been enrolled in the non-ECP arm of the
initial randomized trial and who had experienced
progression of cutaneous manifestations or had
an inadequate response to 12 or more weeks of
standard therapy. Secondary objectives were safety
and efficacy of ECP used in conjunction with standard
immunosuppressive therapy. ECP treatment was per-
formed using the UVAR XTS photopheresis system
(Therakos), as previously described [16]. ECP therapy
was administered 3 times during the first week, then
twice weekly on consecutive days during weeks 2
through 12, and then twice every month until week
24. Study endpoints were the median percentage
change from baseline in the TSS during 12 and 24
weeks of ECP treatment assessed by an ordinal
50-point whole-body scoring system by a specifically
trained medical professional blinded to treatment, as
previously reported [16,19], at study weeks 2, 4, 6,
8, 10, 12, 16, 20, and 24. Other evaluations included
corticosteroid-sparing effects of ECP, as documented
by at least a 50% decrease of corticosteroid dose from
baseline, complete, and partial response of cutaneous
chronic GVHD, and response of extracutaneousmanifestations of cGVHD to 12 and 24 weeks of ECP
treatment, respectively. All skin assessments to
determine the TSS were performed by trained health
care professionals blinded to the treatment given,
and all responses of cutaneous and extracutaneous
manifestations were evaluated by clinical investigators
according to the same criteria and rigor of monitoring
as in the initial randomized study [16]. Changes in oral
mucosa, lungs, eyes, joints, liver, and gastrointestinal
tract involvement during ECP therapy were assessed
by the clinical investigator according to resolved,
improved, stable, or worsened. Complete and partial
resolution of cutaneous manifestations of cGVHD
were defined as previously reported [16]. Safety assess-
ments includedvital signs, blood counts, chemistry tests,
and adverse events.
Statistical Methods
The safety dataset consisted of all patients who
were enrolled in the study and signed an informed
consent (n 5 29). The efficacy (modified intent-to-
treat, MITT) dataset consisted of all patients who
had at least 1 postenrollment TSS determination, at
least 1 ECP treatment, and a baseline (pre-ECP-treat-
ment) corticosteroid dose documented (n 5 24). All
descriptive analyses were based on observed data. In
the case of missing data, the last observation carried
forward method was used. Continuous variables
were summarized by the median and range. Categoric
variables were summarized by the number and per-
centage of patients in each category. Additional analy-
ses were performed comparing this treatment cohort
with the non-ECP treatment arm or the ECP treat-
ment arm of the initial randomized trial. For compar-
ison of the TSS responses to standard non-ECP
therapy and ECP treatment of the randomized study,
data from the same 29 patients were culled from the
non-ECP therapy arm of the initial randomized trial
and compared with data of the crossover open-label
ECP study.RESULTS
Twenty-nine patients with a median age of 43
(range: 20-67) years were enrolled in this open-label
ECP study. Fourteen (48%) patients were male, and
15were female.Nineteen receivedHCT from a related
and 10 from an unrelated donor, and most were
HLA-identical (93%). Stem cell sources consisted of
bone marrow in 8 (28%) and peripheral blood in 21
(72%) of patients. Diagnosis at HCT included acute
leukemia (n5 5), chronic leukemia (n5 6), Hodgkin’s
disease (n 5 11), and myelodysplastic syndrome
(n 5 7). Chronic GVHD characteristics of the cohort
are summarized in Table 1. Ninety percent of patients
had extensive cGVHD by the Seattle modified criteria
Table 1. Chronic Graft-versus-Host Disease Characteristics
Characteristic Study Population
Number of Patients 29
Onset Type, n (%)
- Progressive 11 (38)
- Quiescent (interrupted) 15 (52)
- De novo 3 (10)
Severity at initial diagnosis, n (%)
- Limited 3 (10)
- Extensive 26 (90)
Extracutaneous involvement, n (%)
- Ocular 15 (52)
- Gastrointestinal 2 (7)
- Liver 6 (21)
- Lung 4 (14)
- Oral mucosa 20 (69)
- Joint 12 (41)
Median days from transplantation to
onset of chronic GVHD (range)
161 (81-951)
Median months from onset of chronic
GVHD to first ECP treatment (range)
26 (4-79)
Median baseline total skin score*
(range)
8.5 (1.0-18.5)
Median baseline corticosteroid dose in
mg/day* (range)
15.5 (2-25)
Median duration of corticosteroid use
before enrollment (weeks) (range)
70 (21-335)
Concomitant immunosuppressive
therapy, n (%)
- Cyclosporin A (CSA) 4 (14)
- Mycophenolate mofetil (MMF) 6 (21)
- Corticosteroids 24 (86)
- CSA, MMF, or corticosteroids 26 (93)
Corticosteroid status in initial
randomized study† n, (%)
- Refractory 2 (7)
- Intolerant 11 (38)
- Dependent 17 (59)
Reason for entering crossover ECP
study, n (%)
- Cutaneous disease progression 6 (21)
- Inadequate response to standard
therapy
23 (79)
n indicates number; CSA, cyclosporin A; MMF, mycophenolate mofetil;
ECP, extracorporeal photopheresis; GVHD, graft-versus-host disease.
*Information is available on 24 patients (modified intent-to-treat
population).
†Some patients qualified for more than 1 category.
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cGVHD and first ECP treatment was 26 (range:
4-79) months. All patients had cutaneous involvement
with a median baseline TSS score of 8.5 (range: 1.0-Table 2. Cutaneous Response to Crossover ECP and Steroid-Spari
Number of patients
Cutaneous response
- Complete and partial response (nonblind clinical investigator assessment), n (%
- Median percent change in TSS from baseline (blind observer)
Corticosteroid-sparing effect
$50% Reduction in corticosteroid dose, n (%)
$50% Reduction in corticosteroid dose and corticosteroid dose < 10 mg/day.
ECP indicates extracorporeal photopheresis; TSS, Total Skin Score; n, numbe
*Twenty-four out of 29 patients had baseline TSS and/or baseline steroid dose
†Includes 3 patients with missing baseline TSS who had investigator assessme
‡Includes 5 patients with missing baseline TSS who had investigator assessme18.5). Nineteen of the 29 patients (65.5%) exhibited
deep sclerosis (grade 4, hidebound skin) or moveable
sclerosis (grade 3) on the baseline skin assessment.
Other frequent cGVHD manifestations included
eyes in 15 (52%) patients, oral mucosa in 20 (69%),
and joints in 12 (41%), respectively. Twenty-six
(93%) patients had concomitant immunosuppressive
therapy at start of ECP, consisting of cyclosporine A
(CSA) in 4 (14%), mycophenolate mofetil (MMF) in
6 (21%), corticosteroids in 24 (86%), and CSA,
MMF, or corticosteroids in 26 (93%), respectively. Pa-
tients were enrolled into the crossover open-label ECP
study after a median of 70 (range: 21 to 335) weeks of
corticosteroid therapy for cGVHD and had a median
daily corticosteroid dose of 15.5 (range: 2-25) mg, re-
spectively. None of the patients received additional
therapy for GVHD between the initial randomized
study (standard therapy without ECP of original
study) and the start of the open-label ECP treatment.
Cutaneous Response and Corticosteroid-
Sparing Effects of Crossover Open-Label
ECP Treatment
As shown in Table 2, complete and partial cutane-
ous responses by investigators’ assessment were
observed in 7 of 27 (26%) and 9 of 29 (31%) patients
at weeks 12 and 24 of ECP treatment, respectively.
The TSS declined, reaching a median percent change
compared with a baseline of 27.9% and 225.8% at
weeks 12 and 24 of open-label ECP (Figure 2). Four
of 24 (17%) and 8 of 24 (33%) patients achieved
a $50% reduction in corticosteroid dose at weeks
12 and 24. In addition, 4 of 24 (17%) and 6 of 24
(25%) patients achieved both a $50% reduction in
corticosteroid dose and an end-of-study daily cortico-
steroid dose of\10 mg as shown in Table 2.
Response of Extracutaneous Manifestations of
cGVHD
Table 3 summarizes the response rates in extracu-
taneous manifestations of cGVHD by investigators’
assessment at weeks 12 and 24 of crossover open-ng
Weeks after Start of ECP
12 24
24* 24*
) 7/27† (26) 9/29‡ (31)
27.9 225.8
4/24 (17) 8/24 (33)
4/24 (17) 6/24 (25)
r.
documented (modified-intent-to-treat population).
nts at baseline and week 12.
nts at baseline and week 24.
Figure 2. Comparison of percent decrease in total skin score (TSS) be-
tween patients of initial non-ECP standard therapy and crossover open-
label ECP treatment.
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complete and partial resolution of cGVHD were ob-
served in oral mucosal, liver, and lung involvement.
Response rates further increased at week 24 for all
organ involvements except for liver and lung.
Trajectory of cGVHDManifestations Before and
after Crossover to the ECP Open-Label Study
We analyzed the trajectory of cGVHD among the
29 patients during the standard therapy alone (non-
ECP arm of the initial randomized study) and after
they crossed over to the open-label ECP study. As
shown in Figure 2, there was only a modest decrease
in the TSS by a median of 28.5% during the initial
non-ECP period of 12 weeks compared with 27.9%
during 12 weeks of open-label ECP therapy
(P 5 .90). However, there was a progressive improve-
ment in the TSS during weeks 16 to 24 of open-label
ECP treatment, suggesting a cumulative response
over time. Although more patients in the open-label
ECP study achieved a $50% reduction in corticoste-
roid dose by week 12 compared with the initial
non-ECP period (4 vs 1), these differences were notTable 3. Complete and Partial Response of Extracutaneous Manife
Weeks after Start of ECP
Oral Mucosa Liver
12 13/20 (65) 3/6 (50)
24 14/20 (70) 3/6 (50)
ECP indicates extracorporeal photopheresis; GI, gastrointestinal tract.
*One patient did not have an assessment of joint at week 12 but did have thasignificantly different (P 5 .17). Of note, significantly
more patients in the open-label ECP study (7 of 27,
26%) compared with the initial non-ECP period
(2 of 24, 8%) achieved a complete or partial skin re-
sponse, as assessed by the investigators (P 5 .04). As
shown in Figure 3, significantly more patients achieved
complete or partial responses at week 12 in oral
mucosa (65% vs 27%, P 5 .009) and ocular involve-
ment (27% vs 7%, P 5 .04) after crossing over to the
open-label ECP treatment compared with the prior
non-ECP period, respectively.
To put into perspective the responses observed in
cutaneous cGVHD in patients treated later with
ECP (current crossover open-label study) and patients
treated earlier with ECP (ie, patients randomized to
the ECP arm in previously reported initial study,
[16]), a comparison of the median changes in TSS be-
tween these 2 groups was performed and revealed no
significant differences. In addition, complete and par-
tial skin responses and corticosteroid-sparing effects
were comparable between these 2 patient cohorts.
Similar comparisons between complete and partial re-
sponse rates in extracutaneous manifestations of
cGVHD between patients treated with earlier versus
later ECP are presented in Figure 4.
Safety
Three serious adverse events consisting of 1 case of
bronchopneumonia andEscherichia coli urinary tract in-
fection each and 1 vascular access problem were attrib-
uted to ECP treatment. ECP was well tolerated and
did not result in discontinuation of treatment in any
patient in the study. During the 24 weeks of ECP treat-
ment, no patient experienced recurrence of the
original disease.DISCUSSION
The primary objective of the present study was to
offer an open-label access to ECP to patients with
histologically confirmed cGVHD who were initially
assigned to the standard non-ECP therapy arm of
a prior reported randomized study [16] and who had
experienced either an inadequate response or progres-
sion of cutaneous GVHD while receiving standard
treatment. Twenty-nine patients who crossed over tostations to Crossover ECP
Lungs Ocular Joint GI Tract
Numbers (%)
3/4 (75) 4/15 (27) 4/11* (36) 1/2 (50)
2/4 (50) 7/15 (47) 5/12 (42) 2/2 (100)
t assessment at week 24.
Figure 3. Complete and partial response of extracutaneous manifesta-
tions during standard non-ECP therapy and after crossover to adjunct
ECP: comparison of results after 12 weeks.
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enced progressive improvement in both cutaneous and
extracutaneous manifestations of cGVHD. Improve-
ment in cutaneousGVHDwas evidenced by both a de-
cline in the median TSS after weeks 12 and 24 of
crossover ECP therapy and by a 57% overall complete
or partial cutaneous response by investigators’ assess-
ment. Previous reports on the use of ECP in
corticosteroid-refractory cGVHD have found similar
response rates [8-13,20]. Progressive improvement in
cutaneous GVHD manifestation observed in our
study, as well as the higher response rates reported in
other studies with prolonged treatment with ECP
[8,11,12], suggest that continuation of ECP beyond
24 weeks may have resulted in further benefit in
patients with longer duration of cutaneous cGVHD
such as in this study cohort.
Responses of extracutaneous manifestations of
cGVHD were observed in patients’ livers, lungs, and
eyes, with the highest responses in oral mucosal
involvement. These results are consistent with prior
reports in both adults and children [8,9,10,21].
Few reports are available on the use of ECP in
treatment of bronchiolitis obliterans syndrome
(BOS) associated with cGVHD [9,12,13,21-27].Figure 4. Impact of time to initiate ECP on complete and partial re-
sponse rates of extracutaneous manifestations: comparison of early ver-
sus late start of ECP. Early start represents patients given ECP in the
initial randomized study, whereas late start of ECP represents patients
initially given 12 weeks of non-ECP standard treatment and then crossed
over to ECP therapy.The response seen in 2 of 4 patients with BOS in
our study is, however, encouraging, considering
limited therapeutic options and the poor prognosis
associated with this serious complication [28]. None-
theless, the efficacy of ECP in BOS needs to be deter-
mined in prospective studies with a larger cohort.
Our findings of the corticosteroid-sparing effects
of ECP in patients with long-lasting cGVHD
are encouraging and consistent with prior reports
[8,9,11,12,16,21]. In a prospective study by Foss and
colleagues [12], either a reduction or discontinuation
of immunosuppressive medications was reported in
80% of patients treated with ECP for cGVHD. Inter-
pretation, however, of the steroid-sparing effect of an
open-label treatment needs to be taken with caution
because of potential investigator bias. For instance,
the taper of corticosteroids in the current study was
based on the status of the GVHD manifestations at
the discretion of the treating physician who was not
blinded to the treatment administered. The National
Institutes of Health consensus on cGVHD proposed
that a fixed, predefined algorithm for corticosteroid ta-
per would be necessary in future studies if steroid-
sparing is an endpoint for treatment efficacy, unless
the trial is blinded [29]. To our knowledge, this is
the first study that analyzed the trajectory of cGVHD
manifestations in patients initially treated prospec-
tively with standard therapy and then crossed over to
receive ECP treatment. Significantly higher responses
in the skin (26% vs 8%, P5 .04), oral mucosa (65% vs
27%, P 5 .009), and ocular involvement (27% vs 7%,
P 5 .04) were observed at 12 weeks after the crossing
over to ECP treatment compared with the same previ-
ous period when these patients were receiving standard
therapy alone. Despite longer duration of cGVHD,
responses observed in many affected organs in our
study were comparable to previously reported ones
[12]. Furthermore, one may speculate that improved
results in patients with corticosteroid-refractory
cGVHD may be attainable by starting ECP therapy
at an earlier course of the disease. This is in line with
recently published recommendations of the German/
Austrian/Swiss consensus conference on salvage
therapy of cGVHD [7]. In view of the excellent safety
profile of ECP in the current and previous reports
[8-13,16,20-27], and that ECP treatment has
not been associated with increased infectious
complications nor with potential negative impact on
the graft-versus-leukemia/tumor effect [8,9,16,20],
the use of ECP as second-line therapy of
corticosteroid-refractory cGVHD seems justified.
Moreover, considering the significant toxicities associ-
ated with most of the systemic immunosuppressive
agents used for corticosteroid-refractory cGVHD [7],
ECP compares favorably with the main limitation of
the need for an adequate venous access and the logistics
in delivering such therapy. Recently, Sierra and
Biol Blood Marrow Transplant 17:1775-1782, 2011 1781ECP in Long-Lasting Chronic GVHDcolleagues reported a cost-effectiveness analysis on
treatment of cGVHD in Spain, which compared ECP
to rituximab and imatinib as a third-line treatment
strategy [30]. These observations, however, have to be
confirmed by other investigators using different novel
immunosuppressive strategies and considering the dif-
ferences in treatment costs among various countries.
In conclusion, progressive improvement in cutane-
ous and extracutaneous corticosteroid-refractory
cGVHD was observed after a 24-week course of
ECP in patients who previously had no clinical im-
provement or exhibited worsening in cGVHD while
receiving standard immunosuppressive therapy alone.
These results support findings of the previous ran-
domized trial and support the use of ECP in
corticosteroid-refractory cGVHD patients.ACKNOWLEDGMENTS
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